CY1110400T1 - Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων - Google Patents

Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων

Info

Publication number
CY1110400T1
CY1110400T1 CY20081100948T CY081100948T CY1110400T1 CY 1110400 T1 CY1110400 T1 CY 1110400T1 CY 20081100948 T CY20081100948 T CY 20081100948T CY 081100948 T CY081100948 T CY 081100948T CY 1110400 T1 CY1110400 T1 CY 1110400T1
Authority
CY
Cyprus
Prior art keywords
ranolazine
medicine
numbers
preparation
treatment
Prior art date
Application number
CY20081100948T
Other languages
English (en)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of CY1110400T1 publication Critical patent/CY1110400T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Παρέχονται μέθοδοι για τη θεραπευτική αντιμετώπιση των αρρυθμίων συμπεριλαμβανομένων των ταχυκαρδιών, όπως η ιδιοπαθής κοιλιακή ταχυκαρδία, η κοιλιακή μαρμαρυγή, και η Torsade de Pointes (TdP) με ένα τρόπο που ελαχιστοποιεί τις ανεπιθύμητες παρενέργειες.
CY20081100948T 2002-04-04 2008-09-03 Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων CY1110400T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30
EP03723907A EP1490066B1 (en) 2002-04-04 2003-04-04 Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias

Publications (1)

Publication Number Publication Date
CY1110400T1 true CY1110400T1 (el) 2015-04-29

Family

ID=29255318

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100948T CY1110400T1 (el) 2002-04-04 2008-09-03 Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων

Country Status (20)

Country Link
US (2) US20030220344A1 (el)
EP (3) EP2198866A1 (el)
JP (1) JP4608217B2 (el)
KR (2) KR20040099395A (el)
CN (2) CN100548300C (el)
AT (2) ATE397932T1 (el)
AU (3) AU2003230810B2 (el)
CA (1) CA2481192C (el)
CY (1) CY1110400T1 (el)
DE (2) DE60321550D1 (el)
DK (2) DK1930007T3 (el)
ES (2) ES2345573T3 (el)
HK (1) HK1120390A1 (el)
IL (1) IL197406A0 (el)
MX (1) MXPA04009637A (el)
NO (1) NO330953B1 (el)
NZ (1) NZ535610A (el)
PT (2) PT1490066E (el)
SI (2) SI1490066T1 (el)
WO (1) WO2003086401A1 (el)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
KR101030943B1 (ko) * 2002-05-21 2011-04-28 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여
AU2004303882A1 (en) * 2003-12-18 2005-07-07 Gilead Palo Alto, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
CA2586840A1 (en) * 2004-11-09 2006-05-18 Cv Therapeutics, Inc. Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
CA2606740A1 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
JP2010514696A (ja) * 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
US20100056536A1 (en) * 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US20150148352A1 (en) * 2012-08-14 2015-05-28 Cellixbio Private Limited Compositions and methods for the treatment angina and cardiovascular conditions
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
MX2016001302A (es) 2013-08-01 2016-04-07 Gilead Sciences Inc Compuesto y metodos para tratar el sindrome de qt largo.
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
KR101617683B1 (ko) 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE142497T1 (de) * 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
AU7650294A (en) * 1993-09-24 1995-04-10 University Of British Columbia, The Aminocyclohexylesters and uses thereof
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
BR0108452A (pt) * 2000-02-18 2003-04-01 Cv Therapeutics Inc Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
MXPA02011339A (es) * 2000-05-19 2003-04-25 Amylin Pharmaceuticals Inc Tratamiento del sindrome coronario agudo con glp-1.
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
SI1490066T1 (sl) 2008-10-31
HK1120390A1 (en) 2009-04-03
JP4608217B2 (ja) 2011-01-12
ES2345573T3 (es) 2010-09-27
NO330953B1 (no) 2011-08-22
DK1490066T3 (da) 2008-10-13
AU2011202135A1 (en) 2011-05-26
ATE470445T1 (de) 2010-06-15
AU2003230810A1 (en) 2003-10-27
DK1930007T3 (da) 2010-08-30
JP2005528393A (ja) 2005-09-22
DE60321550D1 (de) 2008-07-24
PT1930007E (pt) 2010-08-17
KR20040099395A (ko) 2004-11-26
US20030220344A1 (en) 2003-11-27
CN1646127A (zh) 2005-07-27
US20100004255A1 (en) 2010-01-07
EP2198866A1 (en) 2010-06-23
EP1930007B1 (en) 2010-06-09
WO2003086401A1 (en) 2003-10-23
DE60332975D1 (de) 2010-07-22
CA2481192A1 (en) 2003-10-23
ES2304507T3 (es) 2008-10-16
CA2481192C (en) 2012-07-03
IL197406A0 (en) 2011-07-31
EP1930007A1 (en) 2008-06-11
PT1490066E (pt) 2008-07-22
CN101843619A (zh) 2010-09-29
NZ535610A (en) 2006-05-26
MXPA04009637A (es) 2005-07-14
NO20044783L (no) 2004-11-03
AU2009201065B2 (en) 2011-07-21
SI1930007T1 (sl) 2010-08-31
AU2009201065A1 (en) 2009-04-09
ATE397932T1 (de) 2008-07-15
KR20100119804A (ko) 2010-11-10
EP1490066B1 (en) 2008-06-11
EP1490066A1 (en) 2004-12-29
CN100548300C (zh) 2009-10-14
AU2003230810B2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CY1110400T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
EP1803485A3 (en) Method for discriminating between ventricular and supraventricular arrhythmias
ATE517658T1 (de) Arrythmie-klassifizierung und therapiewahl
WO2004062479A3 (en) Non-invasive heart treatment device
WO2002003872A3 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
EE200200203A (et) Südame arütmia ravis kasutatavad uued oksabispidiinühendid
EE200300504A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
ATE298339T1 (de) ß3,7-DIAZABICYCLO(3.3.0)OCTANE UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGENß
PL1744736T3 (pl) Sposób leczenia zespołu suchego oka i zapalenia błony naczyniowej oka
EP1684735A4 (en) COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIES INDUCED BY PHYSICAL EXERCISE
ATE415959T1 (de) Herg1-kanal-öffner zur behandlung von herzarrythmien
EE200300495A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
EE200300506A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
EP1363528A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF HEART DISEASES
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
CY1115214T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
CN206261182U (zh) 一种具有消毒功能的鞋柜
ATE330667T1 (de) Aktive medizinische vorrichtung des typs implantierbarer defibrillator/kardioverter mit mitteln zur detektion von nachtherapie-sinus- tachykardien
NO20030057D0 (no) Nye bispidinforbindelser og deres anvendelse ved behandling av hjertearytmier
ATE497784T1 (de) Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen
EE200100674A (et) Bispidiini uued arütmiavastased ühendid, mida kasutatakse südame arütmia ravis
EE200100678A (et) Bispidiini uued arütmiavastased ühendid, mida kasutatakse südame arütmia ravis
AU2003265321A8 (en) Treatments and methods for the treatment, diagnosis and prophylaxis